Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.40 |
| ▸ | MPEG1 | Q2M385 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65638 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL1578876 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL12501883 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL1578870 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL14720387 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL36399 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL1578823 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL1578445 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL1578738 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL465095 | 1.00 | ACHE (0.50) | ACHEBACE1ALOX5PTGS2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469723-B | Cationically curable compositions with latent reducing agents exhibiting low cure temperatures | 汉高股份有限及两合公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20230114308-A1 | Flux-Compatible Epoxy-Anhydride Adhesives Compositions for Low-Gap Underfill Applications | HENKEL AG & CO KGAA (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-115715313-A | Flux compatible epoxy-anhydride adhesive compositions for low gap underfill applications | 汉高股份有限及两合公司 | 2023-02-24 | — | — | CN | disclosed |
| US-11542268-B2 | Cationically curable compositions with latent reducing agent demonstrating low cure temperature | HENKEL AG & CO. KGAA (DE) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542268-B2 | Cationically curable compositions with latent reducing agent demonstrating low cure temperature | CHIT1, SGMS2, LTA | ACHE 59/4885BACE1 2724/4885ALOX5 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.